How Accurate Is Fine-Needle Biopsy in Malignant Neoplasia of the Pancreas?

Parsons, Livingston; Palmer, C. Harvey

doi:10.1001/archsurg.1989.01410060043009

Cited by 43 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These techniques have high specificity with a low risk of procedure related complications. [95][96][97] There are however two concerns regarding transperitoneal techniques, particularly relevant to patients with small and potentially resectable tumours. Firstly, there is a risk of a false negative result.…”

Section: Tissue Diagnosismentioning

confidence: 99%

Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas

Ireland¹

2005

Gut

196

View full text Add to dashboard Cite

Section: Tissue Diagnosismentioning

confidence: 99%

Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas

Ireland¹

2005

Gut

196

View full text Add to dashboard Cite

“…Percutaneous fine needle aspiration of pancreatic masses is useful in selected patients. The technique is safe and generally reliable, 37,38 but is of limited value in patients in whom surgical exploration for attempted resection or palliation is planned. The reason for not using fine needle aspiration cytology or biopsy in potentially resectable lesions is two‐fold.…”

Section: Diagnosis and Stagingmentioning

confidence: 99%

Pancreatic cancer: state-of-the-art care

Lillemoe

Yeo

Cameron

2000

CA: A Cancer Journal for Clinicians

124

View full text Add to dashboard Cite

(CA Cancer J Clin 2000;50:241-268.) IntroductionPancreatic carcinoma is the fourth leading cause of cancer mortality in the US, with more than 28,000 people deaths attributed to the disease each year.1,2 Considered by many to be one of the deadliest malignancies, pancreatic cancer is associated with a death:incidence ratio of approximately .99.3 Despite this grim picture, significant advances have been made in recent years, both in our understanding of the pathogenesis of the disease and in its clinical management. This article reviews the epidemiology and risk factors of pancreatic cancer, as well as recent developments in the field of molecular genetics and the influence of growth factors on disease progression. Moreover, it serves to update the current thinking about the management of pancreatic cancer, including diagnosis and staging, surgical resection, adjuvant therapy, and palliation. Epidemiology and Risk FactorsThe incidence of pancreatic cancer increased in the US nearly three-fold from 1920 to 1978. Since that time, rates have remained constant, with approximately nine new cases diagnosed per 100,000 population.1 By contrast, in nearly all European countries, the incidence of pancreatic cancer has continued to rise.The risk factors for pancreatic cancer have been extensively studied (Table), 4 with advancing age perhaps the strongest risk factor. Incidence rates for pancreatic cancer increase steadily with age, with over 80% of cases occurring between the ages of 60 and 80. The diagnosis of pancreatic cancer in individuals younger than age 40 is uncommon.The incidence and mortality rates for both male and female African Americans with pancreatic cancer are higher than for whites. Although gender differences in pancreatic cancer incidence have been equalizing over recent years, the disease still occurs more frequently in men. Incidence and mortality rates have increased in women since 1974 while having stabilized or decreased slightly in white men.Several studies in US populations C A C a n c e r J C l i n 2 0 0 0 ; 5 0 : 2 4 1 -2 6 8

show abstract

“…In the majority of cases, the extent of disease identified by the combined use of these imaging techniques is sufficient to preclude surgery. If surgery is deemed inappropriate and a cure is not in prospect, diagnosis should be confirmed by percutaneous trans‐abdominal fine needle aspiration (FNA) or biopsy 52 –58 . Such confirmation is essential, not only to obtain more accurate data for prognosis, but also to exclude less common types of pancreatic tumour such as lymphoma or neuroendocrine tumours which may be amenable to other treatment modalities.…”

Section: Imagingmentioning

confidence: 99%

Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer

Haycox

Lombard

Neoptolemos

et al. 1998

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Pancreatic cancer is the tenth most prevalent malignancy and the fifth most common cause of cancer death in the developed world. Less than 10% of patients survive for more than 1 year following diagnosis and the 5-year survival rate (0.4%) is the lowest of any cancer. The poor prognosis associated with this diagnosis led in the past to therapeutic nihilism on the part of clinicians who were all too aware of the limitations of their available therapeutic strategies. Breaking this therapeutic impasse requires a significant expansion in the knowledge of clinicians concerning the pathogenesis and behaviour of pancreatic cancer. Recent advances in the scientific understanding of the aetiology of pancreatic cancer has facilitated progress towards the development of promising and innovative approaches to the early detection and diagnosis of pancreatic cancer. While acknowledging that pancreatic cancer will continue to present significant challenges to both scientists and clinicians in the foreseeable future, it is becoming increasingly clear that recent advances in our scientific knowledge base holds the potential to significantly improve prognosis for patients. The challenge facing both scientists and clinicians is how best to translate such promising scientific advances into survival and quality of life benefits to patients.

show abstract

How Accurate Is Fine-Needle Biopsy in Malignant Neoplasia of the Pancreas?

Cited by 43 publications

References 6 publications

Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas

Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas

Pancreatic cancer: state-of-the-art care

Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer

Contact Info

Product

Resources

About